ArticleMolecular pharmacology2024
Abstract read
In one paragraph
Article in Molecular pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alternative splicing in voltage-gated sodium channels: mechanisms, regulatory networks and therapeutic implications.Annals of medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Nicholas DenommeDepartment of Pharmacology (N.D., S.B., A.A., L.L.I.), Michigan Psychedelic Center (M-PsyC) (N.D., L.L.I.), Life Sciences Institute (C.C.H., A.A.), University of Michigan, Ann Arbor, Michigan; Promega Corporation, Fitchburg, Wisconsin (R.F.O.); Usona Institute, Fitchburg, Wisconsin (A.M.S.); Department of Cell Biology, Neurobiology, and Anatomy. Medical College of Wisconsin, Milwaukee, Wisconsin (H.A.B., J.D.M.); Department of Neurology and Neurologic Sciences, Stanford University, Stanford, California (J.M.H.); and Alexander Shulgin Research Institute, Lafayette, California (P.F.D., W.B.C., N.V.C.).
Ciria C HernandezDepartment of Pharmacology (N.D., S.B., A.A., L.L.I.), Michigan Psychedelic Center (M-PsyC) (N.D., L.L.I.), Life Sciences Institute (C.C.H., A.A.), University of Michigan, Ann Arbor, Michigan; Promega Corporation, Fitchburg, Wisconsin (R.F.O.); Usona Institute, Fitchburg, Wisconsin (A.M.S.); Department of Cell Biology, Neurobiology, and Anatomy. Medical College of Wisconsin, Milwaukee, Wisconsin (H.A.B., J.D.M.); Department of Neurology and Neurologic Sciences, Stanford University, Stanford, California (J.M.H.); and Alexander Shulgin Research Institute, Lafayette, California (P.F.D., W.B.C., N.V.C.).
Hailey A BockDepartment of Pharmacology (N.D., S.B., A.A., L.L.I.), Michigan Psychedelic Center (M-PsyC) (N.D., L.L.I.), Life Sciences Institute (C.C.H., A.A.), University of Michigan, Ann Arbor, Michigan; Promega Corporation, Fitchburg, Wisconsin (R.F.O.); Usona Institute, Fitchburg, Wisconsin (A.M.S.); Department of Cell Biology, Neurobiology, and Anatomy. Medical College of Wisconsin, Milwaukee, Wisconsin (H.A.B., J.D.M.); Department of Neurology and Neurologic Sciences, Stanford University, Stanford, California (J.M.H.); and Alexander Shulgin Research Institute, Lafayette, California (P.F.D., W.B.C., N.V.C.).
Rachel F OhanaDepartment of Pharmacology (N.D., S.B., A.A., L.L.I.), Michigan Psychedelic Center (M-PsyC) (N.D., L.L.I.), Life Sciences Institute (C.C.H., A.A.), University of Michigan, Ann Arbor, Michigan; Promega Corporation, Fitchburg, Wisconsin (R.F.O.); Usona Institute, Fitchburg, Wisconsin (A.M.S.); Department of Cell Biology, Neurobiology, and Anatomy. Medical College of Wisconsin, Milwaukee, Wisconsin (H.A.B., J.D.M.); Department of Neurology and Neurologic Sciences, Stanford University, Stanford, California (J.M.H.); and Alexander Shulgin Research Institute, Lafayette, California (P.F.D., W.B.C., N.V.C.).
Shreeya BakshiDepartment of Pharmacology (N.D., S.B., A.A., L.L.I.), Michigan Psychedelic Center (M-PsyC) (N.D., L.L.I.), Life Sciences Institute (C.C.H., A.A.), University of Michigan, Ann Arbor, Michigan; Promega Corporation, Fitchburg, Wisconsin (R.F.O.); Usona Institute, Fitchburg, Wisconsin (A.M.S.); Department of Cell Biology, Neurobiology, and Anatomy. Medical College of Wisconsin, Milwaukee, Wisconsin (H.A.B., J.D.M.); Department of Neurology and Neurologic Sciences, Stanford University, Stanford, California (J.M.H.); and Alexander Shulgin Research Institute, Lafayette, California (P.F.D., W.B.C., N.V.C.).
Alexander M SherwoodDepartment of Pharmacology (N.D., S.B., A.A., L.L.I.), Michigan Psychedelic Center (M-PsyC) (N.D., L.L.I.), Life Sciences Institute (C.C.H., A.A.), University of Michigan, Ann Arbor, Michigan; Promega Corporation, Fitchburg, Wisconsin (R.F.O.); Usona Institute, Fitchburg, Wisconsin (A.M.S.); Department of Cell Biology, Neurobiology, and Anatomy. Medical College of Wisconsin, Milwaukee, Wisconsin (H.A.B., J.D.M.); Department of Neurology and Neurologic Sciences, Stanford University, Stanford, California (J.M.H.); and Alexander Shulgin Research Institute, Lafayette, California (P.F.D., W.B.C., N.V.C.).
John D McCorvyDepartment of Pharmacology (N.D., S.B., A.A., L.L.I.), Michigan Psychedelic Center (M-PsyC) (N.D., L.L.I.), Life Sciences Institute (C.C.H., A.A.), University of Michigan, Ann Arbor, Michigan; Promega Corporation, Fitchburg, Wisconsin (R.F.O.); Usona Institute, Fitchburg, Wisconsin (A.M.S.); Department of Cell Biology, Neurobiology, and Anatomy. Medical College of Wisconsin, Milwaukee, Wisconsin (H.A.B., J.D.M.); Department of Neurology and Neurologic Sciences, Stanford University, Stanford, California (J.M.H.); and Alexander Shulgin Research Institute, Lafayette, California (P.F.D., W.B.C., N.V.C.).
Paul F DaleyDepartment of Pharmacology (N.D., S.B., A.A., L.L.I.), Michigan Psychedelic Center (M-PsyC) (N.D., L.L.I.), Life Sciences Institute (C.C.H., A.A.), University of Michigan, Ann Arbor, Michigan; Promega Corporation, Fitchburg, Wisconsin (R.F.O.); Usona Institute, Fitchburg, Wisconsin (A.M.S.); Department of Cell Biology, Neurobiology, and Anatomy. Medical College of Wisconsin, Milwaukee, Wisconsin (H.A.B., J.D.M.); Department of Neurology and Neurologic Sciences, Stanford University, Stanford, California (J.M.H.); and Alexander Shulgin Research Institute, Lafayette, California (P.F.D., W.B.C., N.V.C.).
Wyeth B CallawayDepartment of Pharmacology (N.D., S.B., A.A., L.L.I.), Michigan Psychedelic Center (M-PsyC) (N.D., L.L.I.), Life Sciences Institute (C.C.H., A.A.), University of Michigan, Ann Arbor, Michigan; Promega Corporation, Fitchburg, Wisconsin (R.F.O.); Usona Institute, Fitchburg, Wisconsin (A.M.S.); Department of Cell Biology, Neurobiology, and Anatomy. Medical College of Wisconsin, Milwaukee, Wisconsin (H.A.B., J.D.M.); Department of Neurology and Neurologic Sciences, Stanford University, Stanford, California (J.M.H.); and Alexander Shulgin Research Institute, Lafayette, California (P.F.D., W.B.C., N.V.C.).
Jacob M HullDepartment of Pharmacology (N.D., S.B., A.A., L.L.I.), Michigan Psychedelic Center (M-PsyC) (N.D., L.L.I.), Life Sciences Institute (C.C.H., A.A.), University of Michigan, Ann Arbor, Michigan; Promega Corporation, Fitchburg, Wisconsin (R.F.O.); Usona Institute, Fitchburg, Wisconsin (A.M.S.); Department of Cell Biology, Neurobiology, and Anatomy. Medical College of Wisconsin, Milwaukee, Wisconsin (H.A.B., J.D.M.); Department of Neurology and Neurologic Sciences, Stanford University, Stanford, California (J.M.H.); and Alexander Shulgin Research Institute, Lafayette, California (P.F.D., W.B.C., N.V.C.).
Andrew AltDepartment of Pharmacology (N.D., S.B., A.A., L.L.I.), Michigan Psychedelic Center (M-PsyC) (N.D., L.L.I.), Life Sciences Institute (C.C.H., A.A.), University of Michigan, Ann Arbor, Michigan; Promega Corporation, Fitchburg, Wisconsin (R.F.O.); Usona Institute, Fitchburg, Wisconsin (A.M.S.); Department of Cell Biology, Neurobiology, and Anatomy. Medical College of Wisconsin, Milwaukee, Wisconsin (H.A.B., J.D.M.); Department of Neurology and Neurologic Sciences, Stanford University, Stanford, California (J.M.H.); and Alexander Shulgin Research Institute, Lafayette, California (P.F.D., W.B.C., N.V.C.).
Lori L IsomDepartment of Pharmacology (N.D., S.B., A.A., L.L.I.), Michigan Psychedelic Center (M-PsyC) (N.D., L.L.I.), Life Sciences Institute (C.C.H., A.A.), University of Michigan, Ann Arbor, Michigan; Promega Corporation, Fitchburg, Wisconsin (R.F.O.); Usona Institute, Fitchburg, Wisconsin (A.M.S.); Department of Cell Biology, Neurobiology, and Anatomy. Medical College of Wisconsin, Milwaukee, Wisconsin (H.A.B., J.D.M.); Department of Neurology and Neurologic Sciences, Stanford University, Stanford, California (J.M.H.); and Alexander Shulgin Research Institute, Lafayette, California (P.F.D., W.B.C., N.V.C.).ORCID 0000-0002-9479-6729
Nicholas V CozziDepartment of Pharmacology (N.D., S.B., A.A., L.L.I.), Michigan Psychedelic Center (M-PsyC) (N.D., L.L.I.), Life Sciences Institute (C.C.H., A.A.), University of Michigan, Ann Arbor, Michigan; Promega Corporation, Fitchburg, Wisconsin (R.F.O.); Usona Institute, Fitchburg, Wisconsin (A.M.S.); Department of Cell Biology, Neurobiology, and Anatomy. Medical College of Wisconsin, Milwaukee, Wisconsin (H.A.B., J.D.M.); Department of Neurology and Neurologic Sciences, Stanford University, Stanford, California (J.M.H.); and Alexander Shulgin Research Institute, Lafayette, California (P.F.D., W.B.C., N.V.C.) drnick@shulginresearch.net.ORCID 0000-0001-7593-6063
Funding
Role of SCN1B in Inherited EpilepsyR37NS076752 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ISOM, LORI L. · 2017 to 2023
$4.8MStructure-based Design of Selective Serotonin Biased Agonists as Chemical Probes for Psychedelic PotentialR01MH133849 · NIMH · MEDICAL COLLEGE OF WISCONSIN · PI John D McCorvy · 2023 to 2026
$2.1MNIMH NIH HHS R01 MH133849NINDS NIH HHS R37 NS076752
Abstract
Bipolar disorder impacts millions of patients in the United States but the mechanistic understanding of its pathophysiology and therapeutics is incomplete. Atypical antipsychotic serotonin
Indexed as
Receptor, Serotonin, 5-HT2AAnimalsCricetulusHEK293 CellsHumansMaleMiceMice, Inbred C57BLSerotonin 5-HT2 Receptor AntagonistsVoltage-Gated Sodium ChannelsReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor AntagonistsVoltage-Gated Sodium Channels
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.